1-chlorooct-1-en-3-one | 2656-70-4

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1-chlorooct-1-en-3-one
• 英文别名: 1-Chloro-1-octen-3-one
• CAS: 2656-70-4
• 化学式: C₈H₁₃ClO
• 分子量: 160.644
• InChiKey: YLTBAANDCZGTCR-UHFFFAOYSA-N

物化性质

• 沸点：
  94-95 °C(Press: 15 Torr)
• 密度：
  1.0014 g/cm3

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  10
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1-chlorooct-1-en-3-one 在 sodium hydroxide 作用下， 生成 2-庚酮
  参考文献：
  名称：

  Wakayama; Maekawa, Kogyo Kagaku zasshi / Journal of the Society of Chemical Industry, 1955, vol. 58, p. 716

  摘要：

  DOI：
• 作为产物：
  描述：

  己酰氯 、 乙炔 在 三氯化铝 作用下， 以 四氯化碳 为溶剂， 以95%的产率得到1-chlorooct-1-en-3-one
  参考文献：
  名称：

  通过钯催化的交叉偶联对双环烯酮衍生物进行严格的区域和立体控制的α-烯基化反应，并将其应用于（±）-碳环素的正式合成中

  摘要：

  通过经由Zr促进的烯炔双环化-羰基化，Pd催化的双环烯酮的α-烯基化和共轭物还原来制备已知的高级中间体15，可以实现卡巴西林的正式合成。

  DOI：

  10.1016/s0040-4020(98)00347-0

文献信息

• 11-(2-Hydroxyethylthio)prostenoic acid E series derivatives
  申请人：American Cyanamid Company

  公开号：US04154959A1

  公开（公告）日：1979-05-15

  This disclosure describes certain 11-(2-hydroxyethylthio)-9-keto-prostenoic acid E series derivatives, and their intermediates, useful as bronchodilators and inflammatory medeator release inhibitors.

  本披露描述了某些11-(2-羟乙基硫基)-9-酮-前列酸E系列衍生物及其中间体，它们可用作支气管扩张剂和炎症介质释放抑制剂。
• 11-(2-Hydroxyethylthio) prostenoic acid E series derivatives
  申请人：American Cyanamid Company

  公开号：US04154954A1

  公开（公告）日：1979-05-15

  This disclosure describes certain 11-(2-hydroxyethylthio)-9-keto-prostenoic acid E series derivatives, and their intermediates, useful as bronchodilators and inflammatory medeator release inhibitors.

  本公开说明了某些11-(2-羟乙基硫基)-9-酮-前列腺酸E系列衍生物及其中间体，可用作支气管扩张剂和炎症介质释放抑制剂。
• 11 Hydroxy methyl 11-deoxyprostaglandin E.sub.1
  申请人：Ayerst, McKenna and Harrison Limited

  公开号：US04161608A1

  公开（公告）日：1979-07-17

  A process for preparing 11-deoxyprostaglandin E.sub.1, E.sub.2 and E.sub.3 and analogs thereof is realized by treating an appropriate di(lower)alkyl 3-(optionally substituted)-2-formylcyclopropane-1,1-dicarboxylate with an ylid prepared from a Wittig reagent of formula (AlkO).sub.2 POCH.sub.2 CO--(c)-CH.sub.3 in which Alk is an alkyl containing one to three carbon atoms and (c) is either (CH.sub.2).sub.q wherein q is an integer from 1 to 6 or cis CH.sub.2 CH.dbd.CH(CH.sub.2).sub.r wherein r is an integer from 0 to 3 to obtain the corresponding compound of formula: ##STR1## in which R.sup.2 is hydrogen, lower alkyl or CH.sub.2 OR.sup.3 wherein R.sup.3 is lower alkanoyl, R.sup.4 is lower alkyl and (c) is as defined herein. The latter compound is reduced with an alkali metal borohydride to yield the corresponding alcohol derivative. Condensation of this alcohol derivative or preferably its corresponding tetrahydropyran-2-yl ether derivative with a triester of formula CH(COOR.sup.6).sub.2 --(a)-(CH.sub.2)pCOOR in which R and R.sup.6 are lower alkyl, (a) is CH.sub.2 CH.sub.2, cis CH.dbd.CH or C.tbd.C and p is an integer from 2 to 4, gives the corresponding cyclopentanonetriester of formula ##STR2## in which (a), (c), p, R, R.sup.4 and R.sup.6 are as defined herein, R.sup.5 is hydrogen or tetrahydropyran-2-yl, respectively, and R.sup.7 is hydrogen or lower alkyl; the lactonized form of the cyclopentanonetriester being obtained from said alcohol derivative in which R.sup.2 is CH.sub.2 OR.sup.3 wherein R.sup.3 is lower alkanoyl. In the instance when R.sup.5 is tetrahydropyran-2-yl the cyclopentanonetriester is treated with an acid to give the corresponding compound in which R.sup.5 is hydrogen. The instant compound is then treated with a base under aqueous conditions, followed by optional esterification and acylation to give the desired 11-deoxy-prostaglandin derivatives of formula ##STR3## in which (a), (c) and p, are as defined herein, (b) is trans CH.dbd.CH, R is hydrogen or lower alkyl, R.sup.1 is hydrogen or lower alkanoyl and R.sup.2 is hydrogen, lower alkyl or CH.sub.2 OR.sup.3 wherein R.sup.3 is hydrogen or lower alkanoyl. The derivatives possess prostaglandin-like biological activity and methods for their use are given.

  一种制备11-去氧前列腺素E.sub.1，E.sub.2和E.sub.3及其类似物的方法，通过将适当的二（较低）烷基3-（可选取取代基）-2-甲酰基环丙烷-1,1-二羧酸酯与由公式（AlkO）.sub.2 POCH.sub.2 CO-制备的Wittig试剂的ylid处理，其中Alk是含有1至3个碳原子的烷基，（c）是（CH.sub.2）.sub.q，其中q是1至6的整数，或者是顺式CH.sub.2 CH=CH（CH.sub.2）.sub.r，其中r是0至3的整数，以得到相应的化合物的公式：##STR1## 其中R.sup.2是氢，较低的烷基或CH.sub.2 OR.sup.3，其中R.sup.3是较低的烷酰基，R.sup.4是较低的烷基，（c）如上所定义。后一种化合物用碱金属硼氢化物还原，得到相应的醇衍生物。将此醇衍生物或者更好的是其相应的四氢吡喃-2-基醚衍生物与公式CH（COOR.sup.6）.sub.2 --（a）-（CH.sub.2）pCOOR的三酯缩合，其中R和R.sup.6是较低的烷基，（a）是CH.sub.2 CH.sub.2，顺式CH=CH或C.tbd.C，p是2至4的整数，得到相应的环戊烷三酯的公式：##STR2## 其中（a），（c），p，R，R.sup.4和R.sup.6如上所定义，R.sup.5分别为氢或四氢吡喃-2-基，R.sup.7为氢或较低的烷基；从所述醇衍生物中得到环戊烷三酯的内酯形式，其中R.sup.2为CH.sub.2 OR.sup.3，其中R.sup.3为较低的烷酰基。当R.sup.5为四氢吡喃-2-基时，用酸处理环戊烷三酯，得到相应的化合物，其中R.sup.5为氢。然后在水性条件下将瞬时化合物处理为碱，随后进行可选的酯化和酰化，得到所需的公式：##STR3## 其中（a），（c）和p如上所定义，（b）为顺式CH=CH，R为氢或较低的烷基，R.sup.1为氢或较低的烷酰基，R.sup.2为氢，较低的烷基或CH.sub.2 OR.sup.3，其中R.sup.3为氢或较低的烷酰基。这些衍生物具有类似前列腺素的生物活性，并提供了其使用方法。
• 1-Hydroxymethyl-1-oxo-prostane derivatives of the E.sub.2 series
  申请人：American Cyanamid Company

  公开号：US04170597A1

  公开（公告）日：1979-10-09

  Derivatives, analogs, and congeners of prostane having a 1-(hydroxymethyl)-1-oxo-prostane structure in the E.sub.2 series.

  E.sub.2系列中具有1-(羟甲基)-1-氧代-前列腺烷结构的前列腺烷衍生物，类似物和同系物。
• 1-Hydroxymethyl-1-oxo-prostane derivatives of the A.sub.1 series
  申请人：American Cyanamid Company

  公开号：US04197245A1

  公开（公告）日：1980-04-08

  Derivatives, analogs, and congeners of prostane having a 1-(hydroxymethyl)-1-oxo-prostane structure in the A.sub.1 series.

  A.sub.1系列中具有1-(羟甲基)-1-氧代-前列腺烷结构的前列腺烷衍生物，类似物和同系物。